The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Open accessAbstract
In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high levels in lymphoid malignancies. In a model for p185BCR-ABL+ B-acute lymphoid leukemia, we show that CDK6 is part of a transcription complex that induces the expression of the tumor suppressor p16INK4a and the pro-angiogenic factor VEGF-A. This function is independent of CDK6's kinase activity. High CDK6 expression thus suppresses proliferation by upregulating p16INK4a, providing an internal safeguard. However, in the absence of p16INK4a, CDK6 can exert its full tumor-promoting function by enhancing proliferation and stimulating angiogenesis. The finding that CDK6 connects cell-cycle progression to angiogenesis confirms CDK6's central role in hematopoietic malignancies and could underlie the selection pressure to upregulate CDK6 and silence p16INK4a.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, CDK6-specific functions include participating as part of a transcription complex that regulates expression of p16INK4a and VEGF-A[5]”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [5]
In the citing paper
“Moreover, ATP-competitive inhibitors cannot disrupt the scaffolding functions of CDK6, which is important for the transcription function of CDK6 [124, 125].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus
González, S., Klatt, P., Delgado, S., Conde, E., López‐Ríos, F., Sánchez‐Céspedes, M., Méndez, J., Antequera, F., & Serrano, M. (2006) · Nature · doi:10.1038/nature04585 · Cited by 186
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,585
Vascular endothelial growth factor (VEGF) and its receptors
Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,511
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Although p16 is also able to promote oncogene-induced senescence (Campisi, 2012), we failed to obtain any evidence of senescence.”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,711
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature reviews. Cancer · doi:10.1038/35106065 · Cited by 1,510
Self-citationCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Flagged first, then by citations
3 of the 81 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–314 of 314
Kutsebko, D. N., & Glushakov, R. I. (2026) · Malignant tumours · doi:10.18027/2224-5057-2026-067
Kinase inhibition for noncatalytic function
Wang, Z., Zhou, K., & Ding, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43974-2.00011-2
Ringhofer, B., Polzer, W., Prchal‐Murphy, M., Doma, E., Kollmann, S., Gamper, E., Kendler, J., Maw, B. S., Zebedin-Brandl, E. M., Li, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70363
Self-citationMitra, T., Islam, M. T., Tasnim, F., Datta, P. K., Hasan, A. R., Mondal, S., Aktaruzzaman, M., & Sarkar, K. K. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100400
Zhang, Y., Kan, C., Ai, J., Zhou, R., Zhao, Q., Gao, J., Wang, Y., Wu, Z., Qin, X., Ma, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119065
Martínez, J. R., Dey, A., McDermott, M., Rudolph, K. L., & MacLean, A. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.26.734844
Cui, Y., Xie, J., Cai, J., Si, Y., Huang, H., Yu, S., & Sun, H. (2026) · Drug Development Research · doi:10.1002/ddr.70354
Zheng, S., Shen, Z., Wu, Y., Huang, X., Zhang, Z., Liu, J., Wei, Q., Chen, W., Chen, Y., & Xu, L. (2026) · MedComm · doi:10.1002/mco2.70898
Targeted protein degradation as next-generation therapeutic modality for childhood cancer
Couwenbergh, S. T., van den Boogaard, M. L., Swaak, S. E. M., Eising, S., & Molenaar, J. J. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103224
BindingDB (2021) · UC San Diego · doi:10.7270/q2jw8jf1
BindingDB (2021) · UC San Diego · doi:10.7270/q23f4t3t
Metadata
- Authors
- Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., Reichart, U., Mayerhofer, M., Hoeller, C., Zöchbauer-Müller, S., Kerjaschki, D., Bock, C., Kenner, L., Hoefler, G., Freissmuth, M., Green, A. R., Moriggl, R., Busslinger, M., Malumbres, M., & Sexl, V.
- Affiliations
- University of Veterinary Medicine Vienna (AT)
- Comprehensive Cancer Center Vienna (AT)
- Research Institute of Molecular Pathology (AT)
- Medical University of Vienna (AT)
- Austrian Academy of Sciences (AT)
- Ludwig Boltzmann Institute for Cancer Research (AT)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Sexl, Veronika
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 24
- Issue
- 2
- Pages
- 167-181
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC5637299
- OpenAlex
- W2152600133
- Cited by
- 313
- References
- 81
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 27 · 2023: 23 · 2022: 35 · 2021: 33 · 2020: 42 · 2019: 25 · 2018: 20 · 2017: 20 · 2016: 17 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-08-08)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (079249, 100140)
- Medizinische Universität Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- CDK6, CDK4, p16INK4a, VEGF-A, tumor angiogenesis, B-cell acute lymphoblastic leukemia, BCR-ABL, transcriptional regulation, cell cycle, kinase-independent function, lymphoid malignancies, cell proliferation, hematologic malignancies
- MeSH terms
- Animals, Cell Cycle, Humans, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Neoplasms, Neovascularization, Pathologic, Leukemia, B-Cell, Lymphoma, B-Cell, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
